Bone Biologics Corp

Bone Biologics Corporation is a clinical-stage medical device company focused on bone regeneration, specifically in spinal fusion, utilizing its proprietary recombinant human protein, NELL-1. The company's core technology, NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein designed to provide target-specific control over bone regeneration. This platform technology was exclusively licensed worldwide from the UCLA Technology Development Group (UCLA TDG) ¹. The FDA has classified NELL-1/DBM as a device/drug combination product, necessitating an FDA-approved pre-market approval (PMA) application for commercialization in the United States ². The company's business model is currently centered on research and development, with no generated revenues from planned operations since inception ³.

The company's lead product candidate, NB1, is a NELL-1 protein combined with DBM, intended for use in lumbar spinal fusion. NB1 will be sold as a convenience kit containing a single dose vial of freeze-dried NELL-1 recombinant protein on DBM, a diluent, and a syringe of 510(k)-cleared DBM Putty manufactured by MTF Biologics ⁴. The DBM Putty itself is a Class II medical device, regulated under 21 C.F.R. §888.3045, and was cleared by the FDA for spine indications in December 2006 ⁵. The company believes NB1 will address unmet clinical challenges in bone regeneration, particularly for "hard healers," by avoiding rapid, uncontrolled bone growth, less dense bone formation, unwanted bone formation, cysts, swelling, and intense inflammatory responses associated with other bone regeneration compounds ⁶.

Beyond spinal fusion, the company believes NELL-1's characteristics position it for applications in other areas. The global bone graft substitute market, which includes spine implants, is estimated at a $3 billion opportunity ⁷. Non-union trauma cases represent an $8 billion global market opportunity where NELL-1 technology is expected to perform as well as other growth factors ⁸. Additionally, the global osteoporosis market, a major medical challenge, presents an $11.2 billion opportunity, with systemic use of NELL-1 to stimulate bone regeneration and increase bone density potentially having a significant impact ⁹.

For the fiscal year ended December 31, 2025, Bone Biologics Corporation reported no revenues ¹⁰. The company incurred a net loss of $3,108,991 ¹¹ and used net cash in operating activities of $2,691,150 ¹². Total operating expenses were $3,234,942 ¹³, comprising research and development expenses of $1,060,191 ¹⁴ and general and administrative expenses of $2,174,751 ¹⁵. The change in fair value of warrant liability resulted in a gain of $3,967 ¹⁶, and interest income was $121,984 ¹⁷. As of December 31, 2025, the company had cash of $5,334,322 ¹⁸. The company's accumulated deficit since inception reached approximately $88.1 million ¹⁹.

Comparing fiscal year 2025 to 2024, research and development expenses decreased by $1,070,194, from $2,130,385 in 2024 to $1,060,191 in 2025 ²⁰. This 50.23% reduction ²¹ was attributed to lower protein needs during the pilot clinical study. General and administrative expenses increased by $85,975, from $2,088,776 in 2024 to $2,174,751 in 2025 ²², primarily due to the compensation of an independent director appointed in late 2024 ²³. The net loss decreased by 24.40% from $4,112,420 in 2024 to $3,108,991 in 2025 ²⁴. Cash used in operating activities decreased from $4,124,935 in 2024 to $2,691,150 in 2025 ²⁵, mainly due to reduced research and development activities ²⁶.

During 2024, the company announced the treatment of the first subjects in its multicenter, prospective, randomized pilot clinical study of the NB1 bone graft device in Australia ²⁷. This triggered a milestone payment of $100,000 to UCLA TDG for the Feasibility Study ²⁸. In June 2025, the company completed a public offering, issuing 793,750 shares of common stock and pre-funded warrants to purchase 456,250 shares of common stock for $4.00 per share, generating net proceeds of $4,352,792 ²⁹. Additionally, Series D and E warrants to purchase 1,250,000 shares each were issued ³⁰. Through an At The Market (ATM) Offering Agreement, the company sold 52,843 shares of common stock in 2025 for net proceeds of $347,549 ³¹. A 1-for-6 reverse stock split was implemented on June 10, 2025 ³².

Bone Biologics Corporation anticipates continued significant investment in NELL-1 development as it prepares for its pivotal clinical study ³³. The company's available cash is expected to fund its operations into the fourth quarter of 2026 ³⁴. To secure future operations, the company will need to raise additional equity or debt capital, though there is no assurance of success or favorable terms ³⁵.

The primary growth area for the company is the advancement of its lead product candidate, NB1, through clinical studies to achieve FDA approval for lumbar spinal fusion ³⁶. The ongoing pilot clinical study in Australia is evaluating the safety and effectiveness of NB1 in up to 30 adult subjects undergoing transforaminal lumbar interbody fusion (TLIF) for degenerative disc disease (DDD) ³⁷. The primary endpoints are fusion success at 12 months and improvement in the Oswestry Disability Index pain score ³⁸. The company expects to complete this trial 12 months after enrolling the 30th patient ³⁹ and intends to use this data to enable a future, larger U.S. pivotal clinical study, prior to submitting a PMA to the FDA ⁴⁰.

Beyond lumbar spinal fusion, the company believes NELL-1 has broader applications. The global bone graft substitute market, which includes spine implants, represents a $3 billion opportunity ⁴¹. The company also targets the non-union trauma cases market, an $8 billion global opportunity, where it expects NELL-1 technology to perform effectively ⁴². Furthermore, the systemic use of NELL-1 to stimulate bone regeneration and increase bone density could significantly impact the $11.2 billion global osteoporosis market ⁴³. A cervical indication for NB1 is also currently under consideration, aiming to fill a clinical gap created by potentially dangerous inflammatory responses from other commercially available catalytic bone growth agents ⁴⁴.

Operationally, the company expects ongoing significant investment in NELL-1 development ⁴⁵. Operating expenditures for the next twelve months are estimated at $4.9 million ⁴⁶. The company relies on third-party Contract Research Organizations (CROs) to perform GLP non-clinical tests ⁴⁷ and an independent Clinical Research Organization in Australia manages its pilot clinical trial ⁴⁸. The company also relies on third-party contractors for advice and assistance in preparing IDEs and conducting clinical trials ⁴⁹. Both drug and device components of the combination product must be manufactured according to FDA's current Good Manufacturing Practices (cGMPs) ⁵⁰. The company has only two full-time employees and plans to continue relying on independent organizations, advisors, and consultants for regulatory approval, clinical management, manufacturing, marketing, and sales ⁵¹.

Regarding capital allocation, research and development expenses for the year ended December 31, 2025, were $1,060,191 ⁵². The company has an estimated remaining commitment of approximately $251,999 under agreements with Contract Manufacturing Organizations (CMOs), CROs, and other third parties related to its pilot clinical study ⁵³. The company has not historically paid dividends and does not anticipate declaring or paying any cash dividends for the foreseeable future, intending to retain all future earnings for business development and expansion ⁵⁴. The CEO and CFO hold contractual preemptive rights to participate in future financings to maintain their percentage interest in common stock ⁵⁵.

Bone Biologics Corporation faces substantial risks, including its limited operating history and recurring operating losses, which raise substantial doubt about its ability to continue as a going concern, having incurred accumulated losses of approximately $88.1 million since inception ⁵⁶. The company will need to raise substantial additional funds to achieve FDA approval for its lead product, NELL-1/DBM, including costs for a pivotal clinical trial, and there is no assurance that such financing will be available on satisfactory terms ⁵⁷. Product candidates are in early stages of development, and the FDA regulatory approval process is costly, time-consuming, and uncertain, potentially taking five or more years, with no guarantee of success ⁵⁸. Clinical trials may be delayed or terminated due to unacceptable adverse events, difficulties in subject enrollment, or failure to demonstrate adequate effectiveness and safety ⁵⁹. The company operates in a highly competitive medical device industry against larger, more resourced companies, which could lead to reduced sales and pricing pressure ⁶⁰. Intellectual property protection is crucial but uncertain, with existing patents expiring between 2026 and 2033, and new applications facing approval risks and potential challenges ⁶¹. Reliance on third parties for raw materials, manufacturing, and clinical trials introduces risks of delays, increased costs, or inability to secure services ⁶². Non-compliance with extensive healthcare laws and regulations, including anti-kickback and false claims laws, could lead to significant civil and criminal penalties ⁶³. The company's stock price is subject to substantial fluctuation due to clinical trial outcomes, regulatory reviews, financing efforts, and general market conditions ⁶⁴. Future equity issuances could result in substantial dilution for existing stockholders ⁶⁵. There is a risk of delisting from Nasdaq if the company fails to meet continued listing standards, which would negatively impact stock price and liquidity ⁶⁶.

Management's message emphasizes the company's focus on advancing its lead product candidate, NELL-1/DBM, through clinical development to address unmet needs in bone regeneration, particularly in spinal fusion. They highlight the successful initiation of the first-in-man pilot clinical study in Australia during 2024, which evaluated the safety and effectiveness of the NB1 bone graft device in up to 30 adult subjects undergoing transforaminal lumbar interbody fusion for degenerative disc disease ⁶⁷. This milestone triggered a $100,000 payment to UCLA TDG ⁶⁸. Management's strategic priorities include continuing the development of NELL-1 for lumbar spinal fusion, with the intention to use the Australian pilot study data to enable a future, larger U.S. pivotal clinical study prior to submitting a PMA to the FDA ⁶⁹. They also aim to explore broader applications for NELL-1 in areas such as the global bone graft substitute market, non-union trauma cases, and osteoporosis, citing market opportunities of $3 billion ⁷⁰, $8 billion ⁷¹, and $11.2 billion ⁷² respectively. A cervical indication is also under consideration to fill a clinical gap ⁷³. Management acknowledges the need for continued capital funding to facilitate development through the clinical regulatory path ⁷⁴, and expects available cash to fund operations into the fourth quarter of 2026 ⁷⁵.